BioMarin Announces Agreement with German Health Insurance Fu

ROCTAVIAN is First Gene Therapy for Hemophilia to Receive Approved Federal Price in Germany
SAN RAFAEL, Calif., Nov. 28, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. , a global biotechnology...

Related Keywords

Italy , Germany , United States , German , Italian , Traci Mccarty , Jeff Ajer , Andrew Villani , Biomarin Pharmaceutical Inc , Exchange Commission , European Commission , Nasdaq , Drug Administration , Italian Medicines Agency , First Gene Therapy , Receive Approved Federal Price , Biomarin Pharmaceutical , German National Association , Statutory Health Insurance Funds , German Haemophilia Registry , Common Adverse Reactions , Reproductive Potential , Prescribing Information , Important Safety , Quarterly Report , Markets ,